Clinical Trials
16 trialsNCT02343042 2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Active not recruiting
NCT04094961 2026-03-05
Ixazomib + Pomalidomide + Dexamethasone In MM
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT01864018 2025-07-24
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
Phase 1/2 Completed
NCT03732703 2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2 Completed
NCT06050512 2024-11-19
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
University of Pittsburgh
Phase 1/2 Withdrawn
NCT02633059 2024-09-19
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT03225417 2024-08-30
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 1/2 Active not recruiting
NCT02119468 2024-03-15
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT02477215 2020-10-22
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1/2 Completed
NCT03492138 2020-05-29
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Phase 1/2 Terminated
NCT02057640 2019-12-11
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT03856112 2019-03-26
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT01383928 2019-03-21
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
Takeda
Phase 1/2 Completed
NCT01217957 2018-03-14
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Takeda
Phase 1/2 Completed
NCT01335685 2018-01-23
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
Takeda
Phase 1/2 Completed